

Facile method for automated genotyping of single nucleotide polymorphisms by mass spectrometry

Sascha Sauer^{1,2}, David H. Gelfand³, Francis Boussicault², Keith Bauer³, Fred Reichert³ and Ivo G. Gut^{2,*}

¹Freie Universität Berlin, Fachbereich Biologie, Chemie, Pharmazie, Takustrasse 3, 14195 Berlin-Dahlem, Germany,

²Centre National de Génotypage, Bâtiment G2, 2 Rue Gaston Crémieux, 91057 Evry Cedex, France and

³Roche Molecular Systems, Inc., 1145 Atlantic Avenue, Alameda, CA 94501, USA

Received November 27, 2001; Revised and Accepted January 16, 2002

ABSTRACT

In the future, analysis of single nucleotide polymorphisms (SNPs) should become a powerful tool for many genetic applications in areas such as association studies, pharmacogenetics and traceability in the agro-alimentary sector. A number of technologies have been developed for high-throughput genotyping of SNPs. Here we present the simplified GOOD assay for SNP genotyping by matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI). The simplified GOOD assay is a single-tube, purification-free, three-step procedure consisting of PCR, primer extension and phosphodiesterase II digestion followed by mass spectrometric analysis. Due to the application of charge-tag technology, no sample purification is required prior to the otherwise very impurity-sensitive MALDI analysis. The use of methylphosphonate containing primers and ddNTPs or α -S-ddNTPs together with a novel DNA polymerase derived from *Thermotoga maritima* for primer extension allow the fluent preparation of negatively charge-tagged, allele-specific products. A key feature of this polymerase is its preference for ddNTPs and α -S-ddNTPs over dNTPs. The simplified GOOD assay was run with automatic liquid handling at the lowest manageable volumes, automatic data acquisition and interpretation. We applied this novel procedure to genotyping SNPs of candidate genes for hypertension and cardiovascular disease.

INTRODUCTION

With the near completion of the human genome sequencing project, the emphasis of genomic research has shifted towards extraction of information on gene function. Analysis of the relationship between DNA variants and phenotypes, such as disease status or quantitative trait variables, is one of the most powerful tools to obtain such information. Genetic linkage and association or linkage disequilibrium mapping will increasingly rely on the characterization of dense maps of single nucleotide

polymorphisms (SNPs) in very large patient and population cohorts (1–3). In the future, SNP analysis should also become a powerful tool for many applications in areas such as pharmacogenetics and traceability in the agro-alimentary sector (4). Methods for high-quality and low-cost SNP genotyping that are amenable to very high throughput are, thus, of great importance (5). Many methods such as DNA microarrays, gel-based and plate-reader based assays for SNP genotyping have been introduced (6–10).

In principle, mass spectrometry provides one of the most attractive solutions for SNP genotyping because it can be used to obtain direct and rapid measurement of DNA. In particular, matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI) has revolutionized the analysis of biomolecules (11). A number of methods using MALDI have been developed for high-throughput SNP genotyping (12–14). Nevertheless, most SNP genotyping methods using highly impurity-sensitive MALDI analysis require stringent purification procedures, such as magnetic bead separation or reversed-phase binding. In general, purification is expensive and cumbersome in automation (5,10). Here we present the simplified GOOD assay for SNP genotyping using MALDI, which represents a significant advance over previously described procedures (15,16). The simplified GOOD assay is a single-tube, purification-free, three-step method consisting of PCR, primer extension and phosphodiesterase II digestion immediately followed by MALDI analysis. The key to it lies in charge tagging—a chemical modification strategy—which improves the detection sensitivity 100-fold and renders the allele-specific products insensitive to impurities such as the preparation buffers in MALDI. This is achieved by conditioning products to carry either a single excess positive or single excess negative charge (17–19). Here we describe two crucial improvements to the standard GOOD assay: first, the inclusion of extension primers containing methylphosphonate groups on their 3'-ends; secondly, the application of a novel DNA polymerase, Tma 31 FS, derived from *Thermotoga maritima*, for the primer extension reaction. The inclusion of methylphosphonates means that the alkylation reaction with toxic methyl iodide of the standard GOOD assay can be avoided and, thus, the simplified GOOD assay is void of chemistry. Tma 31 FS DNA polymerase accepts methylphosphonate-containing primers and preferentially incorporates ddNTPs over dNTPs. We demonstrate here that

*To whom correspondence should be addressed. Tel: +33 160 87 83 59; Fax: +33 160 87 83 83; Email: ivogut@cng.fr

the simplified GOOD assay can be performed with automatic liquid handling at the lowest manageable volumes, automatic data acquisition and interpretation. The simplified GOOD assay is applied to genotyping SNPs of candidate genes for hypertension and cardiovascular disease.

MATERIALS AND METHODS

Oligonucleotides for PCR were synthesized by MWG Biotech (Ebersberg, Germany) and were all HPSF purified. Oligonucleotides containing methylphosphonates were synthesized by Eurogentec (Liège, Belgium) and PAGE purified. dNTPs, ddNTPs and phosphodiesterase II (from calf spleen) were purchased from Roche Diagnostics (Mannheim, Germany). Platinum™ *Taq* DNA polymerase high fidelity was obtained from Gibco BRL (Karlsruhe, Germany). α -S-ddNTPs were obtained from Biolog (Bremen, Germany). Chemical reagents were purchased from Aldrich (Steinheim, Germany). Tma 31 FS DNA polymerase was provided by Roche Molecular Systems (Alameda, CA).

α -Cyano-4-hydroxy-cinamic acid methyl ester used as MALDI matrix for the simplified GOOD assay is available from Bruker Saxonia Analytik GmbH (Leipzig, Germany). The thermocycling procedures were carried out in an Eppendorf Gradient Thermocycler (Eppendorf, Germany) or a Primus Thermocycler from MWG Biotech (Ebersberg, Germany). A BasePlate robot from The Automation Partnership (Royston, UK) was used for liquid handling of reaction mixtures and for MALDI target preparation.

PCR

β -2-Adrenergic receptor. Human DNA (20 ng), purified as described by Sambrook *et al.* (20), was mixed with 3.5 pmol of the forward primer (5'-CTC GCG GCC CGC AGA GCC) and 3.5 pmol of the reverse primer (5'-GTT GGT GAC CGT CTG CAG ACG CTC), 40 mM Tris base (pH 8.8), 32 mM (NH₄)₂SO₄, 50 mM KCl, 2 mM MgCl₂, 40 μ M dNTPs and 0.2 U *Taq* DNA polymerase in a 10 μ l volume. The reaction was denatured at 95°C for 2 min, then thermocycled for 20 s at 95°C, 30 s at 68°C and 30 s at 72°C, repeating the cycle 30 times.

Platelet/endothelial cell adhesion molecule (PECAM) G+58A. The forward primer (5'-CAT TTT GCA TTT CTC TCC ACC) and reverse primer (5'-GCA GGG CAG GTT CAT AAA TAA G) (2.5 pmol of each) were mixed together with 5 ng genomic DNA, 0.3 μ l Platinum™ *Taq* DNA polymerase high fidelity (10 \times) buffer, 1 mM MgSO₄, 20 μ M dNTPs and 0.1 U Platinum™ *Taq* DNA polymerase high fidelity in a 3 μ l volume. The reaction was denatured for 4 min at 94°C, then thermocycled for 30 s at 94°C, 45 s at 65°C and 30 s at 72°C, repeating 30 times.

Primer extension

For the analysis of SNPs in the β -2-adrenergic receptor gene, 20 pmol of the primer for SNP position 298 (5'-CCC GCC GTG GGT CCGmpCmpC) (mp, methylphosphonate) or 20 pmol of the primer for SNP position 325 (5'-CGC GCA GTC TGG CAGmpGmpT) were mixed with 40 mM Tris base (pH 8.8), 2 mM MgCl₂, 0.2 mM MnCl₂, 100 μ M ddNTPs or α -S-ddNTPs (ddCTP and ddTTP in the case of SNP 298, and ddGTP and ddATP in the case of SNP 325) and 1 U Tma 31 FS DNA polymerase in 10 μ l. These 10 μ l were added to the preceding

PCR. An initial denaturing step of 1 min at 95°C was used followed by 35 cycles of 10 s at 95°C, 30 s at 58°C and 15 s at 72°C.

In the case of the SNP G+58A in the PECAM gene, 5 pmol of primer 5'-ATG TTC CGA GAA GAA CAGmpAmpT and 0.5 U Tma 31 FS DNA polymerase in 2 μ l were added to the 3 μ l PCR using the same reaction conditions as described for the primer extension of the β -2-adrenergic receptor gene.

Phosphodiesterase II digestion. In the case of a reaction volume of 20 μ l, 1.2 μ l of a 0.5 M acetic acid solution was added to the reaction resulting in a pH <7. Then, 3 μ l of phosphodiesterase II, which was previously dialyzed against ammonium citrate (0.1 M pH 6.0), was added and the reaction was incubated for 1 h at 37°C. In the case of the SNP G+58A in the PECAM gene for a reaction volume of 5 μ l, 0.4 μ l of a 0.5 M acetic acid solution and 1.5 μ l of the phosphodiesterase were used.

Preparation for MALDI analysis. One microliter of the reaction mix was diluted in 15 μ l 40% acetonitrile. From this solution 0.5 μ l was transferred onto the matrix-prepared MALDI target plates. For the preparation of the MALDI target, 0.5 μ l of a 1.5% solution of α -cyano-4-hydroxy-cinnamic acid methyl ester matrix in acetone was spotted.

Mass spectrometric analysis. Spectra were recorded on a Bruker Reflex III time-of-flight mass spectrometer. This mass spectrometer is equipped with a Scout MTP™ ion source with delayed extraction. Spectra were recorded in negative ion linear time-of-flight mode. Typical acceleration potentials were 18 kV. For delayed extraction the extraction delay was 200 ns. On average, 10 laser shots per spectrum were accumulated. The GenoTools software was used for automatic data analysis (21).

RESULTS

Recently, we presented the first procedure for SNP genotyping using MALDI detection that does not require purification, termed the GOOD assay (referred to as the standard GOOD assay) (15,16). It requires five reagent additions into a single PCR tube or microtiter plate and incubations or thermocycling. Its major drawback is the requirement of toxic methyl iodide.

The principle of the simplified GOOD assay is illustrated in Figure 1. The procedure starts with a PCR to generate a sufficient amount of template and to reduce the complexity of genomic DNA, thus reducing the risk of mispriming. Immediately following this, primer extension with methylphosphonate containing primers and ddNTPs or α -S-ddNTPs yields allele-specific products. The methylphosphonate bridges of the primers resist the phosphodiesterase II digestion, which is used in the third step to remove the unmodified part of the primers. The resulting products for MALDI analysis have methylphosphonate linkages that are charge-neutral and one negative charge-carrying linkage deriving from the ddNTP or the α -S-ddNTP, rendering the allele-specific products negatively charge-tagged. The crude reaction mixture is transferred onto a MALDI target plate and analyzed. The simplified GOOD assay was applied to genotyping SNPs such as the β -2-adrenergic receptor gene and the PECAM gene (22,23). The analysis of SNPs 298 and 325




Figure 1. The principle of the simplified GOOD assay. The procedure starts with a PCR. The allele-specific step consists of a primer extension reaction with ddNTPs and an oligonucleotide containing methylphosphonates at its 3' end (indicated in black) using the PCR product as template. The unmodified part of the primer is digested by phosphodiesterase II. The methylphosphonate linkages inhibit complete digestion. The resulting product contains a DNA backbone with one negative charge deriving from the phosphate group of the elongated ddNTPs. Thus, the product is negatively charge-tagged. Products are diluted and transferred onto a MALDI target for analysis.




Figure 2. For SNP position 298 of the β -2-adrenergic receptor gene the primer 5'-CCC GCC GTG GGT CCGmpCmpC was extended with ddTTP and ddCTP. The respective products after phosphodiesterase II digestion are GmpCmpC[C/T] and have masses of 1114 Da in the case of incorporation of ddCTPs and 1129 Da in the case of ddTTPs. Spectra of the MALDI analysis of DNA homozygous for C (A), T (B) and heterozygous DNA (C) are shown.

in the β -2-adrenergic receptor gene is shown in Figures 2 and 3. SNP 298 is a C/T polymorphism, while SNP 325 is a G/A polymorphism. Efficient and reliable incorporation during primer extension of all four ddNTPs opposite according bases was observed. The correct analysis of genotypes was confirmed by DNA sequencing using 20 different patient DNAs.




Figure 3. For SNP position 325 of the β -2-adrenergic receptor gene the primer 5'-CGC GCA GTC TGG CAGmpGmpT was extended with ddGTP and ddATP. Products of the simplified GOOD assay, GmpGmpT[G/A], have masses of 1209 Da for extension with ddGTP and 1193 Da for extension with ddATP. The MALDI analysis of DNA homozygous for A (A), G (B) and heterozygous DNA (C) is shown. The spectra were not manipulated.

The simplified GOOD assay was adapted to 384 microtiter plates employing a liquid-handling robot. Thereby, the easy automation of the procedure was demonstrated on the SNP G+58A in the PECAM gene, which is a G/A polymorphism. The starting reaction volume of the PCR was reduced to 3 μ l. The final volume after phosphodiesterase II digestion was 7 μ l. Samples (384) were prepared in one run with four robot movements of a 96-tip head for each of the three liquid dispensings. Microtiter plates were sealed and manually transferred to thermocyclers for the PCR and primer extension reaction, or an incubator for the phosphodiesterase digestion. MALDI targets were prepared by applying α -cyano-4-hydroxy-cinnamic acid methyl ester in a thin layer with the liquid-handling robot. Samples were applied on top of the dry matrix with the same robot. High reproducibility in automatic measurements was observed, accumulating on average only 10 laser shots per spectrum. Even so, spectra with signal-to-noise ratios higher than 20:1 and near baseline isotopic resolutions were obtained in the linear detection mode. Spectra were recorded and alleles called automatically using the GenoTools software (21). Three typical results of the 384 are shown in Figure 4A. In >95% of preparations results were obtained on first pass, which is in a similar range compared with the standard GOOD assay. Missing results were due to PCR failures, probably because of insufficient integrity of genomic DNA templates. The observed genotype frequencies were in good agreement with predictions under the assumption of the Hardy-Weinberg equilibrium.

The simplified GOOD assay demonstrated in Figure 4A was carried out with a primer containing two methylphosphonates at its 3' end. We obtained respective results with a primer containing three methylphosphonates instead of two, thereby shifting masses of allele-specific products 311 Da; from 1177 Da to 1488 Da and from 1193 Da to 1504 Da (Fig. 4B). Additionally, α -S-ddNTPs in place of ddNTPs were used for primer extension under these conditions with comparable




Figure 4. (A) For the SNP G+58A of the PECAM, gene primer 5'-ATG TTC CGA GAA GAA CAGmpAmpT was used. Respective products of the assay were GmpAmpT[G/A] with masses of 1193 Da and 1177 Da. At 1231 and 1215 Da very small potassium adduct signals (+38 Da; indicated with asterisks) were observed. Trace (a) shows the analysis of a DNA homozygous for A, while in trace (b) the analysis of DNA homozygous for G is shown. In (c) the analysis of heterozygous DNA is displayed. The assay was carried out fully automatically starting with a 3 μ l PCR in a 384-well microtiter plate. The final volume of the assay was 7 μ l. The sample was diluted and transferred with the BasePlate robot onto a 384 MTP MALDI target plate. Plates measured automatically need on average 10 laser shots per analysis. (B) The simplified GOOD assay was applied to SNP G+58A of the PECAM gene using an extension primer (5'-ATGTTCCGAGAAGAAGmpAmpT) with three methylphosphonate linkages. Respective products of the assay were AmpGmpAmpT[G/A] with masses 1504 and 1488 m/z. Trace (a) shows the analysis of a DNA homozygous for A while in trace (b) the analysis of DNA homozygous for G is shown. In (c) the analysis of heterozygous DNA is displayed. (C) Alternatively, α -S-ddNTPs can be used as substrates for primer extension. The analysis of patient DNA heterozygous at SNP G+58A using ddGTPs and ddATPs is shown in trace (a) (respective masses of products are 1193 and 1177 Da). The same experiment using α -S-ddGTPs and α -S-ddATPs is shown in trace (b) (respective masses of products are 1209 and 1193 Da). In order to shift masses apart ddATP and α -S-ddGTP were used in the experiment displayed in trace (c) (respective masses of products are 1177 and 1209 Da). Spectra of experiments carried out with ddNTPs or α -S-ddNTPs show similar quality. The spectra were not manipulated.

efficiency of incorporation (Fig. 4C). This provides an added degree of freedom for establishing SNP genotyping multiplexes.

DISCUSSION

The ability to multiplex reactions is of great importance to reduce reagent cost per SNP genotype, analysis time, and in order to make good use of the multi-channel detection capability of MALDI mass spectrometers. Different combinations of ddNTPs and α -S-ddNTPs and different numbers of methylphosphonate linkages allow the separation of alleles. This has interesting implications for the multiplexing of assays, as it adds degrees of freedom. This is similar to that recently demonstrated by another MALDI SNP genotyping method using primer extension, with the advantage that α -S-ddNTPs are less expensive than the fluorescent dideoxy nucleotides used there (24). Haff and coworkers showed that a 12-fold multiplex in the primer extension and subsequent MALDI analysis is possible (25). Nevertheless, the quality of the enzymatic reactions in a multiplex assay depends on the SNPs that are combined. Surrounding DNA sequences have a significant influence on the quality of the PCR. The trade-off for establishing an experiment for SNP genotyping with a high degree of multiplexing is the time required for optimization. The extent of multiplexing at the PCR level and of the primer extension reaction of the simplified GOOD assay is currently under investigation.

Key to the simplified GOOD assay is the Tma 31 FS DNA polymerase. In contrast with other commercially available DNA polymerases (e.g. *Taq*, Thermosequenase, DeepVent), this novel DNA polymerase readily extends primers containing several methylphosphonate linkages on their 3' ends and efficiently incorporates ddNTPs and α -S-ddNTPs over dNTPs. This gives the simplified GOOD assay the added advantage

that residual dNTPs of the PCR do not have to be removed. In the standard GOOD assay this was done by shrimp alkaline phosphatase digestion. Thus one liquid-handling step, the cost of reagents and time is saved. At a 5:1 ratio of dNTPs to ddNTPs, equal signal intensities of the primer extension were observed, yet under the conditions of the simplified GOOD assay the ratio is 1:5 (this experiment was carried out on synthetic templates and is not described in detail). Due to this preference Tma 31 FS DNA polymerase might also be the DNA polymerase of choice for other methods using primer extension after a PCR if the method, like the simplified GOOD assay, has a means of discriminating between the primers used for the PCR and the primer extension.

The simplified GOOD assay presented here is based on the same charge-state concept for DNA detection by MALDI as the standard GOOD assay, but requires fewer steps (three instead of five simple reagent additions). It also allows highly precise MALDI analysis straight from a crude reaction mixture. Simplification is achieved by the introduction of methylphosphonate groups, which are already charge neutral, in place of phosphorothioates in the primers omitting the alkylation step from the standard GOOD assay. A major advantage is that the potentially toxic methylating reagent of the standard GOOD assay is avoided. Due to this, as is demonstrated here, the simplified GOOD assay is even easier to implement for high-throughput applications. It provides a genotyping method with low consumption of DNA and reagents, high accuracy of the results and complete flexibility on the choice of SNPs. The simplified GOOD assay lends itself to further miniaturization and could potentially be executed on a microfluidic device. We are currently implementing the procedures described here in a production line for high-throughput genotyping.

ACKNOWLEDGEMENTS

We thank Laetitia Dorel for technical assistance, and Mark Lathrop and Noah Christian for critical reading of this manuscript. This work was kindly supported by the French Ministry of Research (MENRT). S.S. was funded by the 'Stiftung Stipendienfonds' of the German Chemical Industry.

REFERENCES

1. Sachidanandam,R., Weissman,D., Schmidt,S.C., Kakol,J.M., Stein,L.D., Marth,G., Sherry,S., Mullikin,J.C., Mortimore,B.J., Willey,D.L. *et al.* (2001) A map of human genome sequence variation containing 1.42 million single nucleotide polymorphisms. *Nature*, **409**, 928–933.
2. Collins,F.S., Guyer,M.S. and Charkravarti,A. (1997) Variations on a theme: cataloging human DNA sequence variation. *Science*, **278**, 1580–1581.
3. Hugot,J.P., Chamaillard,M., Zouali,H., Lesage,S., Cezard,J.P., Belaiche,J., Almer,S., Tysk,C., O'Morain,C.A., Gassull,M. *et al.* (2001) Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn's disease. *Nature*, **411**, 599–603.
4. Evans,W.E. and Relling,M.V. (1999) Pharmacogenetics: translating functional genomics into rational therapeutics. *Science*, **286**, 487–491.
5. Chircurel,M. (2001) Faster, better, cheaper genotyping. *Nature*, **412**, 580–582.
6. Landegren,U., Kaiser,R., Caskey,C.T. and Hood,L. (1988) DNA diagnostics—molecular techniques and automation. *Science*, **242**, 229–237.
7. Smith,L.M. (1993) The future of DNA sequencing. *Science*, **262**, 530–532.
8. Wang,D.G., Fan,J.-B., Siao,C.-J., Berno,A., Young,P., Sapolsky,R., Ghandour,G., Perkins,N., Winchester,E., Spencer,J. *et al.* (1998) Large-scale identification, mapping, and genotyping of single nucleotide polymorphisms in the human genome. *Science*, **280**, 1077–1082.
9. Mein,C.A., Barratt,B.J., Dunn,M.G., Siegmund,T., Smith,A.N., Esposito,L., Nutland,S., Stevens,H.E., Wilson,A.J., Phillips,M.S. *et al.* (2000) Evaluation of single nucleotide polymorphism typing with invader on PCR amplicons and its automation. *Genome Res.*, **10**, 330–343.
10. Gut,I.G. (2001) Automation in genotyping of single nucleotide polymorphisms. *Hum. Mutat.*, **17**, 475–492.
11. Karas,M. and Hillenkamp,F. (1988) Laser desorption ionization of proteins with molecular masses exceeding 10,000 daltons. *Anal. Chem.*, **60**, 2299–2303.
12. Haff,L.A. and Smirnov,I.P. (1997) Multiplex genotyping of PCR products with MassTag-labeled primers. *Nucleic Acids Res.*, **25**, 3749–3750.
13. Griffin,T.J., Hall,J.G., Prudent,J.R. and Smith,L.M. (1999) Direct genetic analysis by matrix-assisted laser desorption/ionisation mass spectrometry. *Proc. Natl Acad. Sci. USA*, **96**, 6301–6306.
14. Tang,K., Fu,D.-J., Julien,D., Braun,A., Cantor,C.R. and Koester,H. (1999) Chip-based genotyping by mass spectrometry. *Proc. Natl Acad. Sci. USA*, **96**, 10016–10020.
15. Sauer,S., Lechner,D., Berlin,K., Lehrach,H., Escary,J.L., Fox,N. and Gut,I.G. (2000) A novel procedure for efficient genotyping of single nucleotide polymorphisms. *Nucleic Acids Res.*, **28**, e13.
16. Sauer,S., Lechner,D., Berlin,K., Plançon,C., Heuermann,A., Lehrach,H. and Gut,I.G. (2000) Full flexibility genotyping of single nucleotide polymorphisms by the GOOD assay. *Nucleic Acids Res.*, **28**, e100.
17. Gut,I.G. and Beck,S. (1995) A procedure for selective DNA alkylation and detection by mass spectrometry. *Nucleic Acids Res.*, **23**, 1367–1373.
18. Gut,I.G., Jeffery,W.A., Pappin,D.J.C. and Beck,S. (1997) Analysis of DNA by 'charge tagging' and matrix-assisted laser desorption/ionization mass spectrometry. *Rapid Commun. Mass Spectrom.*, **11**, 43–50.
19. Berlin,K. and Gut,I.G. (1999) Analysis of negatively 'charge tagged' DNA by matrix-assisted laser desorption/ionization mass spectrometry. *Rapid Commun. Mass Spectrom.*, **13**, 1739–1743.
20. Sambrook,J., Fritsch,E.F. and Maniatis,T. (1989) *Molecular Cloning: A Laboratory Manual*, 2nd edn. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY.
21. Pusch,W., Kraeuter,K.O., Froehlich,T., Stalgies,Y. and Kostrzewa,M. (2001) Genotools SNP manager: a new software for automated high-throughput MALDI-TOF mass spectrometry SNP genotyping. *Biotechniques*, **30**, 210–215.
22. Timmermann,B., Mo,R., Luft,F.C., Gerdt,E., Busjahn,A., Omvik,P., Li,G.H., Schuster,H., Wienker,T.F., Hoehe,M.R. and Lund-Johansen,P. (1998) β -2 adrenoceptor genetic variation is associated with genetic predisposition to essential hypertension: The Bergen Blood Pressure Study. *Kidney Int.*, **53**, 1455–1460.
23. Newman,P.J. (1997) The biology of PECAM-1. *J. Clin. Invest.*, **100** (11 Suppl.), S25–S29.
24. Fei,Z. and Smith,L.M. (2000) Analysis of single nucleotide polymorphisms by primer extension and matrix-assisted laser desorption/ionization time-of-flight mass spectrometry. *Rapid Commun. Mass Spectrom.*, **14**, 950–959.
25. Ross,P., Hall,L., Smirnov,I. and Haff,L. (1998) High level multiplex genotyping by MALDI-TOF mass spectrometry. *Nat. Biotechnol.*, **16**, 1347–1351.